Mural Oncology (MURA) versus Its Peers Head to Head Survey

Mural Oncology (NASDAQ:MURA) is one of 1,048 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Mural Oncology to related companies based on the strength of its dividends, valuation, risk, institutional ownership, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Mural Oncology and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mural Oncology	N/A	-$207.45 million	-0.37
Mural Oncology Competitors	$2.54 billion	$150.53 million	-5.14

Mural Oncology’s peers have higher revenue and earnings than Mural Oncology. Mural Oncology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Mural Oncology and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mural Oncology	N/A	-70.10%	-61.30%
Mural Oncology Competitors	-3,620.37%	-274.65%	-33.65%

Insider and Institutional Ownership

80.2% of Mural Oncology shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 0.1% of Mural Oncology shares are owned by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Mural Oncology and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mural Oncology	0	0	3	1	3.25
Mural Oncology Competitors	7607	20882	48486	1193	2.55

Mural Oncology currently has a consensus price target of $16.00, suggesting a potential upside of 377.61%. As a group, “Pharmaceutical preparations” companies have a potential upside of 72.51%. Given Mural Oncology’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Mural Oncology is more favorable than its peers.

Summary

Mural Oncology beats its peers on 8 of the 12 factors compared.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.